Person · CIK 2034056

Shannon T Kelley

General Counsel at Madrigal Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$2M
Noticed on Form 144$1.6M
Bought on Form 4$0
Companies1

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Madrigal Pharmaceuticals MDGLCommon StockDirectly10,397Nov 6, 2026 · Filing · EDGAR
Madrigal Pharmaceuticals MDGLStock Option (Right to Buy)
exercise $434.80, expires Mar 4, 2036, into Common Stock
Directly5,022Mar 4, 2026 · Filing · EDGAR

Sold and noticed by quarter

Shannon T Kelley: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2025 to Q4 2026$505K$0Q1 2025: $217K noticed on Form 144Q1 2025: $215K sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $482K noticed on Form 144Q3 2025: $480K sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $505K noticed on Form 144Q1 2026: $500K sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: notice not machine-readableQ3 2026: $342K sold on Form 4Q4 2026: $431K noticed on Form 144Q4 2026: $431K sold on Form 4Q1 2025Q3 2025Q1 2026Q3 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q4 2026$431K$431K
Q3 2026$342KNot machine-readable
Q1 2026$500K$505K
Q3 2025$480K$482K
Q1 2025$215K$217K

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Madrigal Pharmaceuticals MDGL · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jul 31, 2026 · 1 notice
Nov 6, 20261,077 · ~$431KNov 6, 2026Sold as noticed Sold 1,077 at $400.00 on Nov 6 · $431K Form 4Filing · EDGAR
Madrigal Pharmaceuticals MDGL · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 3 notices
Mar 6, 2026360 · ~$158KMar 6, 2026Sold as noticed Sold 360 at $431.94 on Mar 6 · $155K Form 4Filing · EDGAR
Jan 20, 2026263 · ~$132KJan 20, 2026Sold as noticed Sold 263 at $490.77 on Jan 20 · $129K Form 4Filing · EDGAR
Jan 17, 2025277 · ~$76KJan 17, 2025Sold as noticed Sold 277 at $273.41 on Jan 17 · $76K Form 4Filing · EDGAR
Madrigal Pharmaceuticals MDGL · Morgan Stanley Smith Barney · 10b5-1 plan adopted Nov 7, 2024 · 3 notices
Jan 20, 2026429 · ~$215KJan 20, 2026Sold as noticed Sold 429 at $501.40 on Jan 20 · $215K Form 4Filing · EDGAR
Aug 18, 20251,304 · ~$482KAug 18, 2025Sold as noticed Sold 1,304 in 8 sales, Aug 18 to Aug 18 · $480K Form 4Filing · EDGAR
Mar 3, 2025415 · ~$142KMar 3, 2025Sold as noticed Sold 415 at $335.00 on Mar 3 · $139K Form 4Filing · EDGAR
Sales without a matching Form 144 · 1 sale
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 664 at $514.97 on Aug 17, 2026 · $342KFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Madrigal Pharmaceuticals MDGL General Counsel · filings 2024 to 2026 · sold $2M · $1.6M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Nov 6, 2026Sale under a 10b5-1 plan−1,077$400.00$431K10,397 directFiling · EDGAR
Aug 17, 2026Open-market or private sale−664$514.97$342K11,474 directFiling · EDGAR
Mar 6, 2026Open-market or private sale−360$431.94$155K12,138 directFiling · EDGAR
Mar 4, 2026Grant or award from the company+4,01712,498 directFiling · EDGAR
Mar 4, 2026Grant or award from the company
Stock Option (Right to Buy)
+5,0225,022 directFiling · EDGAR
Jan 20, 2026Sale under a 10b5-1 plan−263$490.77$129K8,910 directFiling · EDGAR
Jan 20, 2026Sale under a 10b5-1 plan−429$501.40$215K8,481 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−458$358.66$164K10,019 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−126$369.64$47K9,893 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−84$370.06$31K9,809 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−84$371.35$31K9,725 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−252$372.44$94K9,473 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−68$374.13$25K9,405 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−190$375.75$71K9,215 directFiling · EDGAR
Aug 18, 2025Sale under a 10b5-1 plan−42$376.62$16K9,173 directFiling · EDGAR
Mar 5, 2025Grant or award from the company+3,18710,477 directFiling · EDGAR
Mar 5, 2025Grant or award from the company
Stock Option (Right to Buy)
+5,3685,368 directFiling · EDGAR
Mar 3, 2025Sale under a 10b5-1 plan−415$335.00$139K7,290 directFiling · EDGAR
Jan 17, 2025Open-market or private sale−277$273.41$76K7,705 directFiling · EDGAR
Aug 15, 2024Grant or award from the company+5,2157,982 directFiling · EDGAR
Aug 15, 2024Grant or award from the company
Stock Option (Right to Buy)
+7,8207,820 directFiling · EDGAR
All 18 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Nov 6, 2026Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Nov 6, 2026Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Aug 20, 2026Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Aug 20, 2026Form 144
Could not read
EDGAR
Mar 6, 2026Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Mar 6, 2026Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 20, 2026Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 20, 2026Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 20, 2026Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Aug 18, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Aug 18, 2025Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Mar 7, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Mar 5, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Mar 3, 2025Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 17, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 17, 2025Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Aug 19, 2024Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Aug 15, 2024Form 3Madrigal Pharmaceuticals MDGLFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.